文献速递头颈甲状腺与浅表介入US

单次高强度聚焦超声治疗持续性或复发性Graves病的两年结局

Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves' disease.
PubMed 文献 · Eur Radiol · 2019-06-17

该回顾性研究纳入2016至2017年接受双侧超声引导高强度聚焦超声消融的75例持续性或复发性Graves病患者,随访至少24个月,24个月复发率为41.3%,无患者发生甲状腺功能减退,3例(4.0%)出现暂时性声带麻痹但2个月内自行恢复;多因素分析显示较高的基线TSHR水平是24个月内疾病复发的独立显著因素(OR=1.079,95%CI=1.014-1.148,p=0.016)。

要点

  • 超声引导HIFU消融甲状腺治疗持续性/复发性Graves病后24个月复发率为41.3%。
  • 治疗后无患者发生甲状腺功能减退,3例(4.0%)出现暂时性声带麻痹但2个月内自行恢复。
  • 较高的基线TSHR水平是24个月内疾病复发的独立显著因素。

核心结论

  • 超声引导甲状腺HIFU消融对于持续性或复发性Graves病患者在较长期内是一种安全且相对有效的治疗。

研究设计与样本

  • 回顾性分析2016至2017年连续接受双侧超声引导HIFU消融的75例持续性或复发性Graves病患者,消融右侧和左侧甲状腺叶中央部分,邻近气管食管沟和颈总动脉区域未消融,随访24个月或更长;检查基线TSH、游离T4、抗甲状腺自身抗体和TSH受体抗体;主要结局为24个月复发率,复发定义为此后出现甲状腺功能亢进(游离T4>23 pmol/L);采用二元logistic回归分析与复发相关的变量。

诊断标准与关键数值

  • 复发定义为随访期间出现甲状腺功能亢进,即游离T4>23 pmol/L;24个月复发率为41.3%(31例患者复发);单因素分析中,较高的每日卡比马唑剂量(OR=1.125,95%CI=1.023-1.237,p=0.015)和较高的基线TSHR水平(OR=1.085,95%CI=1.022-1.152,p=0.007)是疾病复发的显著因素;多因素分析中,较高的基线TSHR水平是24个月内疾病复发的显著独立因素(OR=1.079,95%CI=1.014-1.148,p=0.016)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the longer-term disease relapse of ultrasound (US)-guided high-intensity focused ultrasound (HIFU) ablation as a treatment for persistent/relapsed Graves' disease (GD).

METHODS: After ethics approval, consecutive patients with persistent or relapsed GD who underwent bilateral US-guided HIFU ablation from 2016 to 2017 were retrospectively analyzed. Altogether, 75 patients received HIFU ablation of the central portion of the right and left thyroid lobes with areas near the trachea-esophageal groove and common carotid artery un-ablated. They were followed for 24 months or longer. Baseline thyrotropin (TSH), free T4, anti-thyroid autoantibodies, and TSH receptor (TSHR) antibody were checked. Primary outcome was the 24-month relapse rate. Relapse referred to hyperthyroidism (free T4 (FT4) > 23 pmol/L) afterwards. Variables associated with relapse were analyzed by binary logistic regression.

RESULTS: The cohort comprised mostly females (84.0%) with a mean age of 42.05 ± 10.74 years. The 24-month relapse rate was 41.3% with 31 patients suffering a relapse. No patient suffered from hypothyroidism. Three patients (4.0%) suffered from temporary vocal cord palsy but these injuries recovered spontaneously after 2 months. In univariate analysis, higher daily dose of carbimazole (OR = 1.125, 95% CI = 1.023-1.237, p = 0.015) and higher baseline TSHR level (OR = 1.085, 95% CI = 1.022-1.152, p = 0.007) were significant factors for disease relapse. In the multivariate analysis, higher baseline TSHR level was a significant independent factor for disease relapse within 24 months (OR = 1.079, 95% CI = 1.014-1.148, p = 0.016).

CONCLUSIONS: US-guided HIFU of the thyroid gland was a safe and relatively efficacious treatment in the longer term for patients with persistent or relapsed GD.

KEY POINTS: • US-guided HIFU ablation is relatively efficacious in the longer term. • US-guided HIFU ablation of the thyroid is safe. • Higher TSHR level may lead to higher disease relapse after treatment.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lang BH, Woo YC, Chiu KW, et al. Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves' disease. Eur Radiol. 2019. PMID: 31209622. doi:10.1007/s00330-019-06303-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。